Long-Term Effects of Nucleus Accumbens Deep Brain Stimulation in Treatment-Resistant Depression: Evidence for Sustained Efficacy

Abstract

Deep brain stimulation (DBS) to the nucleus accumbens (NAcc-DBS) was associated with antidepressant, anxiolytic, and procognitive effects in a small sample of patients suffering from treatment-resistant depression (TRD), followed over 1 year. Results of long-term follow-up of up to 4 years of NAcc-DBS are described in a group of 11 patients. Clinical effects, quality of life (QoL), cognition, and safety are reported. Eleven patients were stimulated with DBS bilateral to the NAcc. Main outcome measures were clinical effect (Hamilton Depression Rating Scale, Montgomery-Asperg Rating Scale of Depression, and Hamilton Anxiety Scale) QoL (SF-36), cognition and safety at baseline, 12 months (n ¼ 11), 24 months (n ¼ 10), and last follow-up (maximum 4 years, n ¼ 5). Analyses were performed in an intent-to-treat method with last observation carried forward, thus 11 patients contributed to each point in time. In all, 5 of 11 patients (45%) were classified as responders after 12 months and remained sustained responders without worsening of symptoms until last follow-up after 4 years. Both ratings of depression and anxiety were significantly reduced in the sample as a whole from first month of NAcc-DBS on. All patients improved in QoL measures. One non-responder committed suicide. No severe adverse events related to parameter change were reported. First-time, preliminary long-term data on NAcc-DBS have demonstrated a stable antidepressant and anxiolytic effect and an amelioration of QoL in this small sample of patients suffering from TRD. None of the responders of first year relapsed during the observational period (up to 4 years).

Advanced research on deep brain stimulation in treating mental disorders (Review)

“…Lozano et al (31) demonstrated that it had 55% efficacy, with a follow-up record of 20 patients who underwent the surgery 3-6 years prior. In another group of patients with depression, the anterior limb of the internal capsule was regarded as the target of DBS therapy (32). One month post-surgery, the depressive symptoms of patients remitted were evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS) (33).…”

Deep brain stimulation for obesity: rationale and approach to trial design

“…3,17,57 In most other disease trials for DBS, surgery was offered to patients with severe symptoms in whom medical therapy had failed, and who did not have any other major contraindications to DBS. 47 Trial design would largely depend on the proposed DBS target, but the need for a traditional Phase I clinical trial may be obviated by the fact that a reasonable safety profile has been largely established by previous pilot trials/studies of both LH 90 and NAc 3,17 targets.…”

Deep brain stimulation: a mechanistic and clinical update

“…This trial should help clarify outstanding questions of efficacy and patient selection. Other targets under investigation include the ventral striatum/ nucleus accumbens, 22,23 inferior thalamic peduncle, and habenula.…”